Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level

摘要

Disclosed is the use of temozolomide for the manufacture of a medicament for treating cancer in a patient, wherein the temozolomide is administered according to a dosing regimen and/or schedule based on the patient's MGMT level and, in particular, whether methylation of the MGMT gene is detected in a patient sample. Additional improved dosing regimen and/or schedules for treating patients with temozolomide are also disclosed.